Intismeran autogene with pembrolizumab shows a 49% reduction in recurrence or death risk in high-risk resected melanoma ...
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback